Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVER-MS: Early Intensive vs Escalation Treatment for Relapsing-Remitting Multiple Sclerosis
NCT03535298Phase 4Active, not recruiting
- Sponsor
- Cleveland Clinic
- Start
- Jan 2019
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Cleveland Clinic. Primary endpoints: Normalized whole brain volume loss at 36 months and Expanded Disability Status Scale Plus at 108 months. Started Jan 2019; status: active, not recruiting.
02
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03535298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535298.